ImmunoCellular Therapeutics
Total Awards:
1
Award Value:
$5,391,016
Institution type:
For profit
Short Name:
ImmunoCellular
Awards to the Institution
| Program | Investigator | Award Title | Award Value |
|---|---|---|---|
| Clinical Trial Stage Projects | Anthony Gringeri | A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy | $5,391,016 |
Total: $5,391,016.00 |
